Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost
The role of K+ channels in mediating vasorelaxation induced by two prostacyclin analogues was investigated in guinea-pig aorta. Iloprost caused substantial relaxation of tissues contracted with phenylephrine or 25 mM K+ but not 60 mM K+. In endothelial-denuded tissues, maximal relaxations to ilopros...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 1998-09, Vol.356 (2-3), p.215-224 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 224 |
---|---|
container_issue | 2-3 |
container_start_page | 215 |
container_title | European journal of pharmacology |
container_volume | 356 |
creator | CLAPP, L. H TURCATO, S HALL, S BALOCH, M |
description | The role of K+ channels in mediating vasorelaxation induced by two prostacyclin analogues was investigated in guinea-pig aorta. Iloprost caused substantial relaxation of tissues contracted with phenylephrine or 25 mM K+ but not 60 mM K+. In endothelial-denuded tissues, maximal relaxations to iloprost, cicaprost or isoprenaline were inhibited by approximately 40-50% with tetraethylammonium or iberiotoxin, both blockers of large conductance Ca2+-activated K+ (BKCa) channels. In contrast, the response to forskolin, an activator of adenylate cyclase was marginally inhibited by tetraethylammonium. The K(ATP) channel blocker, glibenclamide significantly augmented the response to iloprost but not cicaprost. These effects were largely inhibited by the EP1 receptor antagonist, 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3(4-pyridinyl)propyl]hydrazide, monohydrochloride (SC-51089) and partially by indomethacin, suggesting that iloprost relaxation is counterbalanced by activation of EP1 receptors, in part through a constrictor prostaglandin. We conclude that BKCa channels play an important role in mediating the effects of iloprost and cicaprost and raises the possibility that cyclic AMP-independent pathways might be involved. |
doi_str_mv | 10.1016/S0014-2999(98)00549-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69972335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69972335</sourcerecordid><originalsourceid>FETCH-LOGICAL-c265t-c931907f664ad93e1030301ef0d0fe582b2b53d77f6447c3fcd8f7a3a0a9f2583</originalsourceid><addsrcrecordid>eNo9kU1rGzEQhkVpSJ20PyGgQygJYVt9rlbHYNIkxJBD27MYa0eNgrzrrGRD_n1lxxgdhJjn1QzPEHLB2Q_OePvzN2NcNcJae2W7a8a0so36RGa8M7ZhhovPZHZEvpCznF9ZpazQp-TUGqOEFjOyvdvGHgePtLxAoXMQNw34ErdQsKdPN9S_wDBgynSd4J0CXcHrONFpTEjjQFfYRyhx-FfjSLeQ_SbBRDEE9CXTMdCYxvU05kJh6KmPHvavr-QkQMr47XCfk7-_7v7MH5rF8_3j_HbReNHq0ngruWUmtK2C3krkTNbDMbCeBdSdWIqllr2phFLGy-D7LhiQwMAGoTt5Tr5__Fu7vm0wF7eK2WNKMOC4ya611ggpdQX1B-jreHnC4NZTXMH07jhzO99u79vtZDrbub1vp2ru4tBgs6wyjqmD4Fq_PNSrG0hhgsHHfMSEEnVVRv4HLIKIaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69972335</pqid></control><display><type>article</type><title>Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>CLAPP, L. H ; TURCATO, S ; HALL, S ; BALOCH, M</creator><creatorcontrib>CLAPP, L. H ; TURCATO, S ; HALL, S ; BALOCH, M</creatorcontrib><description>The role of K+ channels in mediating vasorelaxation induced by two prostacyclin analogues was investigated in guinea-pig aorta. Iloprost caused substantial relaxation of tissues contracted with phenylephrine or 25 mM K+ but not 60 mM K+. In endothelial-denuded tissues, maximal relaxations to iloprost, cicaprost or isoprenaline were inhibited by approximately 40-50% with tetraethylammonium or iberiotoxin, both blockers of large conductance Ca2+-activated K+ (BKCa) channels. In contrast, the response to forskolin, an activator of adenylate cyclase was marginally inhibited by tetraethylammonium. The K(ATP) channel blocker, glibenclamide significantly augmented the response to iloprost but not cicaprost. These effects were largely inhibited by the EP1 receptor antagonist, 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3(4-pyridinyl)propyl]hydrazide, monohydrochloride (SC-51089) and partially by indomethacin, suggesting that iloprost relaxation is counterbalanced by activation of EP1 receptors, in part through a constrictor prostaglandin. We conclude that BKCa channels play an important role in mediating the effects of iloprost and cicaprost and raises the possibility that cyclic AMP-independent pathways might be involved.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(98)00549-4</identifier><identifier>PMID: 9774252</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier</publisher><subject><![CDATA[Animals ; Antineoplastic Agents - antagonists & inhibitors ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Calcium - metabolism ; Cardiovascular system ; Dose-Response Relationship, Drug ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiology ; Epoprostenol - analogs & derivatives ; Epoprostenol - antagonists & inhibitors ; Epoprostenol - pharmacology ; Guinea Pigs ; Hydrazines - pharmacology ; Iloprost - antagonists & inhibitors ; Iloprost - pharmacology ; Isoproterenol - antagonists & inhibitors ; Isoproterenol - pharmacology ; Male ; Medical sciences ; Muscle, Smooth, Vascular - drug effects ; Oxazepines - pharmacology ; Pharmacology. Drug treatments ; Phenylephrine - antagonists & inhibitors ; Potassium Channel Blockers ; Potassium Channels - drug effects ; Potassium Channels - physiology ; Prostaglandin Antagonists - pharmacology ; Tetraethylammonium - pharmacology ; Vasodilation - drug effects ; Vasodilator Agents - antagonists & inhibitors ; Vasodilator Agents - pharmacology ; Vasodilator agents. Cerebral vasodilators]]></subject><ispartof>European journal of pharmacology, 1998-09, Vol.356 (2-3), p.215-224</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c265t-c931907f664ad93e1030301ef0d0fe582b2b53d77f6447c3fcd8f7a3a0a9f2583</citedby><cites>FETCH-LOGICAL-c265t-c931907f664ad93e1030301ef0d0fe582b2b53d77f6447c3fcd8f7a3a0a9f2583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2420717$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9774252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CLAPP, L. H</creatorcontrib><creatorcontrib>TURCATO, S</creatorcontrib><creatorcontrib>HALL, S</creatorcontrib><creatorcontrib>BALOCH, M</creatorcontrib><title>Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>The role of K+ channels in mediating vasorelaxation induced by two prostacyclin analogues was investigated in guinea-pig aorta. Iloprost caused substantial relaxation of tissues contracted with phenylephrine or 25 mM K+ but not 60 mM K+. In endothelial-denuded tissues, maximal relaxations to iloprost, cicaprost or isoprenaline were inhibited by approximately 40-50% with tetraethylammonium or iberiotoxin, both blockers of large conductance Ca2+-activated K+ (BKCa) channels. In contrast, the response to forskolin, an activator of adenylate cyclase was marginally inhibited by tetraethylammonium. The K(ATP) channel blocker, glibenclamide significantly augmented the response to iloprost but not cicaprost. These effects were largely inhibited by the EP1 receptor antagonist, 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3(4-pyridinyl)propyl]hydrazide, monohydrochloride (SC-51089) and partially by indomethacin, suggesting that iloprost relaxation is counterbalanced by activation of EP1 receptors, in part through a constrictor prostaglandin. We conclude that BKCa channels play an important role in mediating the effects of iloprost and cicaprost and raises the possibility that cyclic AMP-independent pathways might be involved.</description><subject>Animals</subject><subject>Antineoplastic Agents - antagonists & inhibitors</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Calcium - metabolism</subject><subject>Cardiovascular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiology</subject><subject>Epoprostenol - analogs & derivatives</subject><subject>Epoprostenol - antagonists & inhibitors</subject><subject>Epoprostenol - pharmacology</subject><subject>Guinea Pigs</subject><subject>Hydrazines - pharmacology</subject><subject>Iloprost - antagonists & inhibitors</subject><subject>Iloprost - pharmacology</subject><subject>Isoproterenol - antagonists & inhibitors</subject><subject>Isoproterenol - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Oxazepines - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenylephrine - antagonists & inhibitors</subject><subject>Potassium Channel Blockers</subject><subject>Potassium Channels - drug effects</subject><subject>Potassium Channels - physiology</subject><subject>Prostaglandin Antagonists - pharmacology</subject><subject>Tetraethylammonium - pharmacology</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - antagonists & inhibitors</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kU1rGzEQhkVpSJ20PyGgQygJYVt9rlbHYNIkxJBD27MYa0eNgrzrrGRD_n1lxxgdhJjn1QzPEHLB2Q_OePvzN2NcNcJae2W7a8a0so36RGa8M7ZhhovPZHZEvpCznF9ZpazQp-TUGqOEFjOyvdvGHgePtLxAoXMQNw34ErdQsKdPN9S_wDBgynSd4J0CXcHrONFpTEjjQFfYRyhx-FfjSLeQ_SbBRDEE9CXTMdCYxvU05kJh6KmPHvavr-QkQMr47XCfk7-_7v7MH5rF8_3j_HbReNHq0ngruWUmtK2C3krkTNbDMbCeBdSdWIqllr2phFLGy-D7LhiQwMAGoTt5Tr5__Fu7vm0wF7eK2WNKMOC4ya611ggpdQX1B-jreHnC4NZTXMH07jhzO99u79vtZDrbub1vp2ru4tBgs6wyjqmD4Fq_PNSrG0hhgsHHfMSEEnVVRv4HLIKIaw</recordid><startdate>19980904</startdate><enddate>19980904</enddate><creator>CLAPP, L. H</creator><creator>TURCATO, S</creator><creator>HALL, S</creator><creator>BALOCH, M</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980904</creationdate><title>Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost</title><author>CLAPP, L. H ; TURCATO, S ; HALL, S ; BALOCH, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c265t-c931907f664ad93e1030301ef0d0fe582b2b53d77f6447c3fcd8f7a3a0a9f2583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - antagonists & inhibitors</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Calcium - metabolism</topic><topic>Cardiovascular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiology</topic><topic>Epoprostenol - analogs & derivatives</topic><topic>Epoprostenol - antagonists & inhibitors</topic><topic>Epoprostenol - pharmacology</topic><topic>Guinea Pigs</topic><topic>Hydrazines - pharmacology</topic><topic>Iloprost - antagonists & inhibitors</topic><topic>Iloprost - pharmacology</topic><topic>Isoproterenol - antagonists & inhibitors</topic><topic>Isoproterenol - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Oxazepines - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenylephrine - antagonists & inhibitors</topic><topic>Potassium Channel Blockers</topic><topic>Potassium Channels - drug effects</topic><topic>Potassium Channels - physiology</topic><topic>Prostaglandin Antagonists - pharmacology</topic><topic>Tetraethylammonium - pharmacology</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - antagonists & inhibitors</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CLAPP, L. H</creatorcontrib><creatorcontrib>TURCATO, S</creatorcontrib><creatorcontrib>HALL, S</creatorcontrib><creatorcontrib>BALOCH, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CLAPP, L. H</au><au>TURCATO, S</au><au>HALL, S</au><au>BALOCH, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1998-09-04</date><risdate>1998</risdate><volume>356</volume><issue>2-3</issue><spage>215</spage><epage>224</epage><pages>215-224</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>The role of K+ channels in mediating vasorelaxation induced by two prostacyclin analogues was investigated in guinea-pig aorta. Iloprost caused substantial relaxation of tissues contracted with phenylephrine or 25 mM K+ but not 60 mM K+. In endothelial-denuded tissues, maximal relaxations to iloprost, cicaprost or isoprenaline were inhibited by approximately 40-50% with tetraethylammonium or iberiotoxin, both blockers of large conductance Ca2+-activated K+ (BKCa) channels. In contrast, the response to forskolin, an activator of adenylate cyclase was marginally inhibited by tetraethylammonium. The K(ATP) channel blocker, glibenclamide significantly augmented the response to iloprost but not cicaprost. These effects were largely inhibited by the EP1 receptor antagonist, 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3(4-pyridinyl)propyl]hydrazide, monohydrochloride (SC-51089) and partially by indomethacin, suggesting that iloprost relaxation is counterbalanced by activation of EP1 receptors, in part through a constrictor prostaglandin. We conclude that BKCa channels play an important role in mediating the effects of iloprost and cicaprost and raises the possibility that cyclic AMP-independent pathways might be involved.</abstract><cop>Amsterdam</cop><pub>Elsevier</pub><pmid>9774252</pmid><doi>10.1016/S0014-2999(98)00549-4</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 1998-09, Vol.356 (2-3), p.215-224 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_69972335 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Antineoplastic Agents - antagonists & inhibitors Antineoplastic Agents - pharmacology Biological and medical sciences Calcium - metabolism Cardiovascular system Dose-Response Relationship, Drug Endothelium, Vascular - drug effects Endothelium, Vascular - physiology Epoprostenol - analogs & derivatives Epoprostenol - antagonists & inhibitors Epoprostenol - pharmacology Guinea Pigs Hydrazines - pharmacology Iloprost - antagonists & inhibitors Iloprost - pharmacology Isoproterenol - antagonists & inhibitors Isoproterenol - pharmacology Male Medical sciences Muscle, Smooth, Vascular - drug effects Oxazepines - pharmacology Pharmacology. Drug treatments Phenylephrine - antagonists & inhibitors Potassium Channel Blockers Potassium Channels - drug effects Potassium Channels - physiology Prostaglandin Antagonists - pharmacology Tetraethylammonium - pharmacology Vasodilation - drug effects Vasodilator Agents - antagonists & inhibitors Vasodilator Agents - pharmacology Vasodilator agents. Cerebral vasodilators |
title | Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A30%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20that%20Ca2+-activated%20K+%20channels%20play%20a%20major%20role%20in%20mediating%20the%20vascular%20effects%20of%20iloprost%20and%20cicaprost&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=CLAPP,%20L.%20H&rft.date=1998-09-04&rft.volume=356&rft.issue=2-3&rft.spage=215&rft.epage=224&rft.pages=215-224&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(98)00549-4&rft_dat=%3Cproquest_cross%3E69972335%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69972335&rft_id=info:pmid/9774252&rfr_iscdi=true |